Lois Mulligan

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Richardson Douglas S; Gujral Taranjit S; Peng Susan; Asa Sylvia L; Mulligan Lois M
Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Hickey Jessica G; Myers Shirley M; Tian Xuefei; Zhu Shu Jun; V Shaw Julie L; Andrew Scott D; Richardson Douglas S; Brettschneider Julia; Mulligan Lois M
RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation.
Gujral Taranjit S; van Veelen Wendy; Richardson Douglas S; Myers Shirley M; Meens Jalna A; Acton Dennis S; Duñach Mireia; Elliott Bruce E; Höppener Jo W M; Mulligan Lois M
A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Lois Mulligan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Richardson Douglas S; Gujral Taranjit S; Peng Susan; Asa Sylvia L; Mulligan Lois M
Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Cancer research 2009;69(11):4861-9.
2009: Hickey Jessica G; Myers Shirley M; Tian Xuefei; Zhu Shu Jun; V Shaw Julie L; Andrew Scott D; Richardson Douglas S; Brettschneider Julia; Mulligan Lois M
RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation.
Genes, chromosomes & cancer 2009;48(5):429-40.
2008: Gujral Taranjit S; van Veelen Wendy; Richardson Douglas S; Myers Shirley M; Meens Jalna A; Acton Dennis S; Duñach Mireia; Elliott Bruce E; Höppener Jo W M; Mulligan Lois M
A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.
Cancer research 2008;68(5):1338-46.
2007: Lai Andrea Z; Gujral Taranjit S; Mulligan Lois M
RET signaling in endocrine tumors: delving deeper into molecular mechanisms.
Endocrine pathology 2007;18(2):57-67.
2006: Gujral Taranjit S; Singh Vinay K; Jia Zongchao; Mulligan Lois M
Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
Cancer research 2006;66(22):10741-9.
2006: Gujral Taranjit S; Mulligan Lois M
Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
Annals of the New York Academy of Sciences 2006;1073():234-40.
2006: Richardson D S; Lai A Z; Mulligan L M
RET ligand-induced internalization and its consequences for downstream signaling.
Oncogene 2006;25(22):3206-11.
2005: Vanhorne Judith B; Andrew Scott D; Harrison Karen J; Taylor Sherryl A M; Thomas Bradley; McDonald Thomas J; Ainsworth Peter J; Mulligan Lois M
A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2.
Oncogene 2005;24(6):1091-7.
2004: Myers Shirley M; Mulligan Lois M
The RET receptor is linked to stress response pathways.
Cancer research 2004;64(13):4453-63.
2002: Andrew Scott D; Capes-Davis Amanda; Delhanty Patric J D; Marsh Deborah J; Mulligan Lois M; Robinson Bruce G
Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway.
Gene 2002;298(1):9-19.
2001: Vanhorne J B; Gimm O; Myers S M; Kaushik A; von Deimling A; Eng C; Mulligan L M
Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease.
Human genetics 2001;108(5):409-15.
2001: Gath R; Goessling A; Keller K M; Koletzko S; Coerdt W; Müntefering H; Wirth S; Hofstra R M; Mulligan L; Eng C; von Deimling A
Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease.
Gut 2001;48(5):671-5.
2001: Gimm O; Dziema H; Brown J; Hoang-Vu C; Hinze R; Dralle H; Mulligan L M; Eng C
Over-representation of a germline variant in the gene encoding RET co-receptor GFRalpha-1 but not GFRalpha-2 or GFRalpha-3 in cases with sporadic medullary thyroid carcinoma.
Oncogene 2001;20(17):2161-70.
2001: Carter M T; Yome J L; Marcil M N; Martin C A; Vanhorne J B; Mulligan L M
Conservation of RET proto-oncogene splicing variants and implications for RET isoform function.
Cytogenetics and cell genetics 2001;95(3-4):169-76.
2001: Mulligan L M
Multiple endocrine neoplasia type 2: molecular aspects.
Frontiers of hormone research 2001;28():81-102.
2000: Hansford J R; Mulligan L M
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.
Journal of medical genetics 2000;37(11):817-27.
2000: Andrew S D; Delhanty P J; Mulligan L M; Robinson B G
Sp1 and Sp3 transactivate the RET proto-oncogene promoter.
Gene 2000;256(1-2):283-91.
2000: Onochie C I; Korngut L M; Vanhorne J B; Myers S M; Michaud D; Mulligan L M
Characterisation of the human GFRalpha-3 locus and investigation of the gene in Hirschsprung disease.
Journal of medical genetics 2000;37(9):674-9.
1999: Perren A; Weng L P; Boag A H; Ziebold U; Thakore K; Dahia P L; Komminoth P; Lees J A; Mulligan L M; Mutter G L; Eng C
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
The American journal of pathology 1999;155(4):1253-60.
1999: Gimm O; Gössling A; Marsh D J; Dahia P L; Mulligan L M; von Deimling A; Eng C
Mutation and deletion analysis of GFR alpha-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumours.
British journal of cancer 1999;80(3-4):383-6.
1999: Myers S M; Salomon R; Goessling A; Pelet A; Eng C; von Deimling A; Lyonnet S; Mulligan L M
Investigation of germline GFR alpha-1 mutations in Hirschsprung disease.
Journal of medical genetics 1999;36(3):217-20.
1999: Feilotter H E; Coulon V; McVeigh J L; Boag A H; Dorion-Bonnet F; Duboué B; Latham W C; Eng C; Mulligan L M; Longy M
Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.
British journal of cancer 1999;79(5-6):718-23.
1998: Feilotter H E; Nagai M A; Boag A H; Eng C; Mulligan L M
Analysis of PTEN and the 10q23 region in primary prostate carcinomas.
Oncogene 1998;16(13):1743-8.
1998: Mulligan L M; Timmer T; Ivanchuk S M; Campling B G; Young L C; Rabbitts P H; Sundaresan V; Hofstra R M; Eng C
Investigation of the genes for RET and its ligand complex, GDNF/GFR alpha-I, in small cell lung carcinoma.
Genes, chromosomes & cancer 1998;21(4):326-32.
1998: Ivanchuk S M; Myers S M; Mulligan L M
Expression of RET 3' splicing variants during human kidney development.
Oncogene 1998;16(8):991-6.
1998: Eng C; Myers S M; Kogon M D; Sanicola M; Hession C; Cate R L; Mulligan L M
Genomic structure and chromosomal localization of the human GDNFR-alpha gene.
Oncogene 1998;16(5):597-601.
1997: Gimm O; Marsh D J; Andrew S D; Frilling A; Dahia P L; Mulligan L M; Zajac J D; Robinson B G; Eng C
Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation.
The Journal of clinical endocrinology and metabolism 1997;82(11):3902-4.
1997: Marsh D J; Zheng Z; Arnold A; Andrew S D; Learoyd D; Frilling A; Komminoth P; Neumann H P; Ponder B A; Rollins B J; Shapiro G I; Robinson B G; Mulligan L M; Eng C
Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors.
The Journal of clinical endocrinology and metabolism 1997;82(9):3025-8.
1997: Ivanchuk S M; Eng C; Cavenee W K; Mulligan L M
The expression of RET and its multiple splice forms in developing human kidney.
Oncogene 1997;14(15):1811-8.
1997: Boccia L M; Green J S; Joyce C; Eng C; Taylor S A; Mulligan L M
Mutation of RET codon 768 is associated with the FMTC phenotype.
Clinical genetics 1997;51(2):81-5.
1997: Dahia P L; Toledo S P; Mulligan L M; Maher E R; Grossman A B; Eng C
Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor alpha complex, in sporadic phaeochromocytomas.
Cancer research 1997;57(2):310-3.
1997: Marsh D J; Mulligan L M; Eng C
RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Hormone research 1997;47(4-6):168-78.
1996: Ivanchuk S M; Myers S M; Eng C; Mulligan L M
De novo mutation of GDNF, ligand for the RET/GDNFR-alpha receptor complex, in Hirschsprung disease.
Human molecular genetics 1996;5(12):2023-6.
1996: Eng C; Clayton D; Schuffenecker I; Lenoir G; Cote G; Gagel R F; van Amstel H K; Lips C J; Nishisho I; Takai S I; Marsh D J; Robinson B G; Frank-Raue K; Raue F; Xue F; Noll W W; Romei C; Pacini F; Fink M; Niederle B; Zedenius J; Nordenskjöld M; Komminoth P; Hendy G N; Mulligan L M
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
JAMA : the journal of the American Medical Association 1996;276(19):1575-9.
1996: Eng C; Foster K A; Healey C S; Houghton C; Gayther S A; Mulligan L M; Ponder B A
Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
British journal of cancer 1996;74(3):339-41.
1996: Eng C; Mulligan L M; Healey C S; Houghton C; Frilling A; Raue F; Thomas G A; Ponder B A
Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma.
Cancer research 1996;56(9):2167-70.
1996: Jackson M S; See C G; Mulligan L M; Lauffart B F
A 9.75-Mb map across the centromere of human chromosome 10.
Genomics 1996;33(2):258-70.
1996: Marsh D J; Andrew S D; Eng C; Learoyd D L; Capes A G; Pojer R; Richardson A L; Houghton C; Mulligan L M; Ponder B A; Robinson B G
Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
Cancer research 1996;56(6):1241-3.
1995: Eng C; Crossey P A; Mulligan L M; Healey C S; Houghton C; Prowse A; Chew S L; Dahia P L; O'Riordan J L; Toledo S P
Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.
Journal of medical genetics 1995;32(12):934-7.
1995: Myers S M; Eng C; Ponder B A; Mulligan L M
Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET.
Oncogene 1995;11(10):2039-45.
1995: Mulligan L M; Marsh D J; Robinson B G; Schuffenecker I; Zedenius J; Lips C J; Gagel R F; Takai S I; Noll W W; Fink M
Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.
Journal of internal medicine 1995;238(4):343-6.
1995: Neumann H P; Eng C; Mulligan L M; Glavac D; Zäuner I; Ponder B A; Crossey P A; Maher E R; Brauch H
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
JAMA : the journal of the American Medical Association 1995;274(14):1149-51.
1995: Attié T; Pelet A; Edery P; Eng C; Mulligan L M; Amiel J; Boutrand L; Beldjord C; Nihoul-Fékété C; Munnich A
Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease.
Human molecular genetics 1995;4(8):1381-6.
1995: Eng C; Mulligan L M; Smith D P; Healey C S; Frilling A; Raue F; Neumann H P; Ponder M A; Ponder B A
Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Clinical endocrinology 1995;43(1):123-7.
1995: Mulligan L M; Ponder B A
Genetic basis of endocrine disease: multiple endocrine neoplasia type 2.
The Journal of clinical endocrinology and metabolism 1995;80(7):1989-95.
1995: Lorenzo M J; Eng C; Mulligan L M; Stonehouse T J; Healey C S; Ponder B A; Smith D P
Multiple mRNA isoforms of the human RET proto-oncogene generated by alternate splicing.
Oncogene 1995;10(7):1377-83.
1995: Eng C; Mulligan L M; Smith D P; Healey C S; Frilling A; Raue F; Neumann H P; Pfragner R; Behmel A; Lorenzo M J
Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma.
Genes, chromosomes & cancer 1995;12(3):209-12.
1995: Eng C; Smith D P; Mulligan L M; Healey C S; Zvelebil M J; Stonehouse T J; Ponder M A; Jackson C E; Waterfield M D; Ponder B A
A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
Oncogene 1995;10(3):509-13.
1994: Feldman G L; Kambouris M; Talpos G B; Mulligan L M; Ponder B A; Jackson C E
Clinical value of direct DNA analysis of the RET proto-oncogene in families with multiple endocrine neoplasia type 2A.
Surgery 1994;116(6):1042-7.
1994: Mulligan L M; Eng C; Attié T; Lyonnet S; Marsh D J; Hyland V J; Robinson B G; Frilling A; Verellen-Dumoulin C; Safar A
Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene.
Human molecular genetics 1994;3(12):2163-7.
1994: Edery P; Attié T; Mulligan L M; Pelet A; Eng C; Ponder B A; Munnich A; Lyonnet S
A novel polymorphism in the coding sequence of the human RET proto-oncogene.
Human genetics 1994;94(5):579-80.
1994: Gardner E; Mulligan L M; Eng C; Healey C S; Kwok J B; Ponder M A; Ponder B A
Haplotype analysis of MEN 2 mutations.
Human molecular genetics 1994;3(10):1771-4.
1994: Dow E; Cross S; Wolgemuth D J; Lyonnet S; Mulligan L M; Mascari M; Ladda R; Williamson R
Second locus for Hirschsprung disease/Waardenburg syndrome in a large Mennonite kindred.
American journal of medical genetics 1994;53(1):75-80.
1994: Marsh D J; Robinson B G; Andrew S; Richardson A L; Pojer R; Schnitzler M; Mulligan L M; Hyland V J
A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families.
Genomics 1994;23(2):477-9.
1994: Attie T; Pelet A; Sarda P; Eng C; Edery P; Mulligan L M; Ponder B A; Munnich A; Lyonnet S
A 7 bp deletion of the RET proto-oncogene in familial Hirschsprung's disease.
Human molecular genetics 1994;3(8):1439-40.
1994: Edery P; Pelet A; Mulligan L M; Abel L; Attié T; Dow E; Bonneau D; David A; Flintoff W; Jan D
Long segment and short segment familial Hirschsprung's disease: variable clinical expression at the RET locus.
Journal of medical genetics 1994;31(8):602-6.
1994: Mulligan L M; Eng C; Healey C S; Ponder M A; Feldman G L; Li P; Jackson C E; Ponder B A
A de novo mutation of the RET proto-oncogene in a patient with MEN 2A.
Human molecular genetics 1994;3(6):1007-8.
1994: Lyonnet S; Edery P; Mulligan L M; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékéte C; Ponder B A; Munnich A
[Mutations of RET proto-oncogene in Hirschsprung disease]
Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie 1994;317(4):358-62.
1994: McMahon R; Mulligan L M; Healey C S; Payne S J; Ponder M; Ferguson-Smith M A; Barton D E; Ponder B A
Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families.
Human molecular genetics 1994;3(4):643-6.
1994: Tunnacliffe A; Jackson M S; Gardner E; Love D R; Moore J K; Mole S E; Mulligan L M; Graham A; Finocchiaro G; Orstavik S
A multiple interval physical map of the pericentromeric region of human chromosome 10.
Human genetics 1994;93(3):313-8.
1994: Eng C; Smith D P; Mulligan L M; Nagai M A; Healey C S; Ponder M A; Gardner E; Scheumann G F; Jackson C E; Tunnacliffe A
Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Human molecular genetics 1994;3(2):237-41.
1994: Edery P; Lyonnet S; Mulligan L M; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékété C; Ponder B A; Munnich A
Mutations of the RET proto-oncogene in Hirschsprung's disease.
Nature 1994;367(6461):378-80.
1994: Mulligan L M; Eng C; Healey C S; Clayton D; Kwok J B; Gardner E; Ponder M A; Frilling A; Jackson C E; Lehnert H
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
Nature genetics 1994;6(1):70-4.
1993: Kwok J B; Gardner E; Warner J P; Ponder B A; Mulligan L M
Structural analysis of the human ret proto-oncogene using exon trapping.
Oncogene 1993;8(9):2575-82.
1993: Mulligan L M; Kwok J B; Healey C S; Elsdon M J; Eng C; Gardner E; Love D R; Mole S E; Moore J K; Papi L
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
Nature 1993;363(6428):458-60.
1993: Mole S E; Mulligan L M; Healey C S; Ponder B A; Tunnacliffe A
Localisation of the gene for multiple endocrine neoplasia type 2A to a 480 kb region in chromosome band 10q11.2.
Human molecular genetics 1993;2(3):247-52.
1993: Gardner E; Papi L; Easton D F; Cummings T; Jackson C E; Kaplan M; Love D R; Mole S E; Moore J K; Mulligan L M
Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2.
Human molecular genetics 1993;2(3):241-6.
1993: Mulligan L M; Gardner E; Smith B A; Mathew C G; Ponder B A
Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2.
Genes, chromosomes & cancer 1993;6(3):166-77.
1992: Mulligan L M; Gardner E; Ponder B A
An SphI polymorphism at the ZNF22 locus.
Human molecular genetics 1992;1(7):551.
1992: Chambers J A; Gardner E; Hauptmann R; Ponder B A; Mulligan L M
TaqI polymorphisms at the annexin VIII locus (ANX8).
Human molecular genetics 1992;1(7):550.
1992: Mulligan L M; Gardner E; Ponder B A
An SphI polymorphism at the vinculin locus (VCL).
Human molecular genetics 1992;1(7):550.
1992: Mulligan L M; Gardner E; Telenius H; Ponder B A
Complementary physical and genetic techniques map the vinculin (VCL) gene on chromosome 10q.
Genomics 1992;13(4):1347-9.
1992: Xu W; Mulligan L M; Ponder M A; Liu L; Smith B A; Mathew C G; Ponder B A
Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis.
Genes, chromosomes & cancer 1992;4(4):337-42.
1991: Mulligan L M; Gardner E; Papi L; Ponder B A
A new polymorphism in the ret protooncogene (RET).
Nucleic acids research 1991;19(20):5795.
1990: Sood R; Mulligan L M; Poon R; White B N; Holden J J
Genetic mapping of two new DNA markers in Xq26-q28 relative to the fragile-X syndrome locus.
American journal of human genetics 1990;47(3):395-402.
1989: Mulligan L; Sood R; Poon R; White B N; Holden J J
Isolation and mapping of a polymorphic DNA sequence, DXS312, to Xq27----Xq28.
Nucleic acids research 1989;17(11):4421.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Lois Mulligan

Research Profile (preview)

Chemicals & Drugs

Disorders

Genes & Molecular Sequences

Anatomy

Physiology

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Lois Mulligan (preview)

All Publications